Post-Stroke Neuropsychiatric & Pain Syndromes

Neuropsychiatric and pain complications affect 30–70% of stroke survivors, yet remain systematically under-recognized and undertreated. Post-stroke depression dramatically reduces rehabilitation participation and independently predicts mortality. Fatigue is the most common complaint of stroke survivors in the chronic phase. Central post-stroke pain is often misdiagnosed or attributed to musculoskeletal causes. Pseudobulbar affect is mistaken for depression. Apathy is confused with laziness or noncompliance. These conditions are within the neurologist’s scope of practice, and recognition alone — even before treatment — improves outcomes by validating the patient’s experience and directing appropriate referrals.

1. Post-Stroke Depression (PSD)

Epidemiology & Impact

Post-stroke depression is the most common neuropsychiatric complication of stroke, affecting approximately one-third of survivors across all time points. A systematic review and meta-analysis of observational studies found pooled prevalence of 33% (95% CI 29–36%), with rates highest at 3–6 months but remaining elevated for years after stroke. Risk factors include stroke severity, degree of physical disability, prior depression, social isolation, female sex, and younger age (loss of expected function). The contribution of lesion location remains debated — early literature emphasized left frontal lesions, but large meta-analyses have not consistently confirmed a lateralization effect.

PSD is not simply a “reaction” to disability. Biological mechanisms contribute directly, including disruption of serotonergic and noradrenergic ascending pathways, neuroinflammation (elevated IL-6, TNF-α, CRP are associated with PSD development), and HPA axis dysregulation. This dual pathogenesis — both reactive and neurobiological — explains why PSD occurs even in patients with mild strokes and good functional recovery.

The clinical impact of untreated PSD is substantial. It independently predicts worse functional recovery (even controlling for stroke severity), increased mortality at 12 and 24 months, reduced participation in rehabilitation, longer hospital stays, greater caregiver burden, and worse quality of life. Conversely, successful treatment of PSD improves ADL performance, supporting the argument that screening and treatment are not optional but essential components of stroke care.

Screening

The 2026 AIS Guideline recommends screening for depressive symptoms in all stroke patients (Class 1, LOE B-NR). This is a new Class 1 recommendation reflecting the strength of evidence linking PSD detection to improved outcomes.

Treatment

Pharmacologic therapy: Multiple meta-analyses and network analyses demonstrate that antidepressants are effective for treating PSD, with SSRIs and tricyclic antidepressants both superior to placebo. Network meta-analyses suggest paroxetine may have the best efficacy profile for PSD specifically, though this finding is limited by heterogeneous comparisons. Antidepressants improve depressive symptoms but are less well tolerated than placebo — monitoring for adverse effects is essential.

Important distinctions from the general depression literature apply to stroke patients:

Non-pharmacologic therapy: Repetitive transcranial magnetic stimulation (rTMS) is effective for PSD treatment, with a meta-analysis of 22 RCTs showing significant reduction in HDS scores. The combination of low-frequency rTMS with antidepressant therapy showed even greater benefit in a meta-analysis of 34 RCTs. Cognitive behavioral therapy (CBT) is effective in meta-analysis but access is limited in acute/inpatient settings. Structured exercise programs also show antidepressant effects.

2. Post-Stroke Fatigue

Post-stroke fatigue (PSF) is the most commonly reported subjective complaint among stroke survivors in the chronic phase, with prevalence estimates of 40–70%. It is a distinct entity from depression, though the two frequently coexist (~50% overlap). PSF is characterized by overwhelming exhaustion that is disproportionate to activity level, not fully explained by exertion, and not reliably relieved by rest. Patients describe a fluctuating, unpredictable energy depletion that fundamentally limits rehabilitation participation, social engagement, and return to work.

Distinguishing Fatigue from Depression

While fatigue is a symptom of depression, PSF occurs independently in a substantial proportion of patients who do not meet criteria for PSD. Key distinguishing features: PSF patients typically retain the desire to do things but lack the energy — they are frustrated by their limitation. Depressed patients often lack the desire itself — they feel hopeless, anhedonic, or worthless. When fatigue and depression coexist, treating the depression may improve but not eliminate the fatigue.

Differential Diagnosis

Before attributing fatigue to the stroke itself, exclude treatable causes: obstructive sleep apnea (prevalence >50% post-stroke, strongly associated with worse recovery and recurrent stroke — screen with STOP-BANG, confirm with polysomnography), medication side effects (beta-blockers, anticonvulsants, benzodiazepines, opioids, centrally acting antihypertensives), hypothyroidism, anemia, deconditioning, uncontrolled diabetes, and chronic infection.

Assessment

No stroke-specific fatigue assessment tool has been validated, but the Fatigue Severity Scale (FSS) — a 9-item questionnaire with 7-point Likert responses — is most commonly used in stroke research. A mean score ≥4 indicates clinically significant fatigue. The Fatigue Assessment Scale (FAS) is an alternative 10-item tool. Both are self-reported and may be limited in patients with aphasia or cognitive impairment.

Management

The evidence base for PSF treatment is disappointingly limited. No pharmacologic intervention has been validated in large RCTs. Current management is largely supportive:

• Energy conservation strategies: Activity pacing (alternating demanding and less demanding tasks), prioritization of important activities, strategic rest periods (short scheduled rests, not prolonged inactivity which worsens fatigue through deconditioning).
• Graded exercise: Paradoxically, structured physical activity reduces fatigue — likely through cardiovascular conditioning, improved sleep quality, and mood enhancement. Start low, increase gradually.
• Sleep optimization: Treat OSA aggressively (CPAP). Address sleep hygiene (consistent wake/bed times, limit napping to <30 min, minimize nighttime disruptions). Screen for restless legs syndrome.
• Pharmacologic trials: Modafinil (100–200 mg AM) and methylphenidate (5–20 mg AM and noon) have been used off-label with limited evidence and mixed results. No large RCTs support routine use. Consider on individual basis if fatigue is severe and non-pharmacologic approaches are insufficient.
• Treat comorbidities: Depression treatment, thyroid replacement, anemia correction, medication review.

3. Pseudobulbar Affect (PBA)

Pseudobulbar affect is defined as involuntary, exaggerated, or incongruent episodes of crying or laughing that are disproportionate to the patient’s actual emotional state. The patient may cry without feeling sad or laugh without feeling amused — or the emotional expression may be wildly out of proportion to the triggering stimulus (e.g., uncontrollable sobbing in response to a mildly touching comment). Prevalence is approximately 15–25% post-stroke and it is frequently misdiagnosed as depression.

Pathophysiology

PBA results from disruption of cortico-ponto-cerebellar circuits that normally modulate the threshold and amplitude of emotional expression. Cortical (prefrontal) areas exert tonic inhibition on brainstem nuclei that generate emotional motor patterns (facial expression, vocalization, respiratory patterns). Lesions anywhere along this pathway — frontal cortex, internal capsule, basis pontis, cerebellum — can release these brainstem generators from cortical control. Unlike depression (where the emotion itself is disordered), in PBA the emotion is normal but the expression is dysregulated.

Diagnosis

The Center for Neurologic Study-Lability Scale (CNS-LS) is a 7-item self-report questionnaire that quantifies PBA severity. Scores range from 7 to 35; a cutoff of ≥13 has been used to identify PBA in clinical trials and can support the clinical diagnosis.

Treatment

Dextromethorphan/quinidine (Nuedexta) is the only FDA-approved treatment for PBA. The combination contains dextromethorphan 20 mg (NMDA antagonist and sigma-1 receptor agonist that modulates emotional expression circuits) and quinidine 10 mg (CYP2D6 inhibitor that prevents rapid hepatic metabolism of dextromethorphan, allowing therapeutic CNS levels). Dosing: 1 capsule daily × 7 days, then 1 capsule BID. Clinical trials demonstrated significant reduction in CNS-LS scores, episode frequency, and quality of life improvement. QTc monitoring is recommended at baseline due to quinidine; avoid in patients with prolonged QTc, heart block, or concurrent QTc-prolonging drugs.

Alternatives: Low-dose tricyclic antidepressants (amitriptyline 25–50 mg at bedtime) and SSRIs (particularly sertraline) have shown benefit in small studies and may be useful when PBA and depression coexist — treating both conditions simultaneously. Response to these agents for PBA typically occurs at lower doses than required for depression treatment.

4. Post-Stroke Apathy

Apathy is defined as a quantitative reduction in goal-directed behavior, cognition, and emotion compared to the patient’s prior level of functioning. It is not sadness, not laziness, and not depression — though it is frequently conflated with all three. Apathy affects approximately 35% of stroke survivors and frequently coexists with depression, but the two are dissociable: apathetic patients may score normally on depression scales, and depressed patients may be highly emotionally reactive (the opposite of apathy).

Diagnostic Criteria (Robert 2018)

Apathy is diagnosed when there is loss of or diminished motivation compared to the patient’s prior functioning, present for ≥4 weeks, in at least 2 of the following 3 domains:

• Goal-directed behavior: Loss of self-initiated actions (doesn’t start activities spontaneously, waits to be told what to do, reduced participation in social/recreational activities previously enjoyed). Not explained by physical disability — a patient who can transfer but doesn’t get out of the wheelchair unless prompted.
• Goal-directed cognitive activity: Loss of spontaneous ideas, plans, curiosity, interest in news or external events, reduced decision-making initiative.
• Emotional blunting: Reduced emotional responsiveness to positive or negative events, flat affect, lack of concern about one’s own condition or others’ circumstances.

These symptoms must not be fully explained by physical disability, substance effects, altered level of consciousness, or a major change in environment.

Clinical Significance

Apathy independently predicts worse rehabilitation outcomes: apathetic patients participate less in therapy, require more prompting, and make slower functional gains even after controlling for depression and stroke severity. Apathy also predicts greater caregiver burden (caregivers often interpret it as the patient “not trying”), increased ADL dependence, and poorer long-term quality of life.

Assessment & Management

Assessment tools include the Apathy Evaluation Scale (AES) — an 18-item scale available in self-report, informant, and clinician versions — and the Dimensional Apathy Scale (DAS). No FDA-approved treatment exists. Evidence-based management is limited:

• Recognition itself is therapeutic: Naming the syndrome for patients and caregivers reduces frustration and prevents the harmful framing of apathy as “not trying hard enough.”
• Structured scheduling: Because apathetic patients lack internal drive, external structure (fixed daily schedules, alarm reminders, caregiver prompts) provides the activation signal they cannot generate themselves.
• Behavioral activation: Gradual, therapist-guided engagement in previously enjoyed activities, starting with low-demand tasks and increasing complexity.
• Pharmacologic trials (limited evidence): Methylphenidate (5–20 mg), donepezil (5–10 mg), and rTMS to left DLPFC have shown promise in small studies but no definitive RCTs exist. Consider on individual basis if apathy severely limits rehabilitation participation.
• Treat comorbid depression: If depression coexists (common), treating it may partially improve apathy — but apathy-specific interventions are usually still needed.

5. Post-Stroke Anxiety

Anxiety affects approximately 25% of stroke survivors and is frequently comorbid with depression (up to 50% overlap). It is independently associated with worse functional outcomes, reduced quality of life, and impaired rehabilitation participation. Post-stroke anxiety often manifests in three patterns:

• Generalized anxiety: Excessive worry about health, recurrent stroke, financial security, caregiver availability. Persistent tension, restlessness, difficulty concentrating.
• Phobic anxiety: Fear of falling (one of the strongest predictors of actual falls, creates a vicious cycle: fear → activity avoidance → deconditioning → increased fall risk), fear of recurrent stroke (avoidance of physical exertion, excessive BP monitoring), agoraphobia (avoidance of public spaces due to embarrassment about disability).
• PTSD-like symptoms: Intrusive memories of the stroke event, hypervigilance about neurological symptoms, avoidance of situations associated with the stroke (e.g., the location where it occurred).

Assessment: GAD-7 (Generalized Anxiety Disorder-7) for generalized anxiety; HADS-A (Hospital Anxiety and Depression Scale — anxiety subscale) for broader anxiety screening. Both can be administered quickly in clinical settings.

Management: SSRIs and SNRIs effectively treat both PSD and anxiety when they coexist — this makes them the pharmacologic treatment of choice when both conditions are present. CBT is effective, particularly for phobic anxiety (structured exposure therapy for fear of falling, psychoeducation about stroke risk for fear of recurrence). Specific fear of falling responds to multifactorial fall prevention programs (demonstrating safety through controlled exposure to challenging balance tasks). Benzodiazepines should be avoided in stroke patients due to cognitive effects, fall risk, and potential interference with neuroplasticity.

6. Cognitive Impairment & Vascular Dementia Screening

Post-stroke cognitive impairment (PSCI) is both common and consequential: up to 40% of stroke survivors have clinically significant cognitive deficits at 3 months, and the risk of dementia is approximately doubled after stroke. Unlike Alzheimer’s disease, vascular cognitive impairment (VCI) preferentially affects executive function, processing speed, and attention — rather than episodic memory. This distinction has practical implications: standard dementia screens like the MMSE, which emphasize memory and orientation, miss the cognitive deficits most characteristic of VCI.

Screening

The Montreal Cognitive Assessment (MoCA) is superior to the MMSE for detecting vascular cognitive impairment because it specifically tests executive function (Trail Making B analog, verbal abstraction, phonemic fluency), attention (serial 7s, digit span, target tapping), and visuospatial/constructional ability — the domains most affected by vascular disease. The 2026 AIS Guideline recommends cognitive screening for all stroke patients. A MoCA score <26 warrants further neuropsychological evaluation; however, the cutoff may need adjustment for education level and age.

Vascular Dementia vs Alzheimer’s Disease

Management: Vascular risk factor control has the strongest evidence for preventing cognitive decline after stroke — BP management, statin therapy, diabetes control, smoking cessation, physical activity. Cognitive rehabilitation (structured exercises targeting impaired domains) shows moderate benefit. Cholinesterase inhibitors (donepezil, rivastigmine) have limited evidence in pure vascular dementia but may benefit mixed (vascular + Alzheimer’s) pathology. Anticholinergic medications should be systematically eliminated — they worsen cognitive impairment and are frequently prescribed in stroke patients (oxybutynin for bladder symptoms, diphenhydramine for sleep).

7. Central Post-Stroke Pain (CPSP)

Central post-stroke pain — formerly “thalamic pain syndrome” or “Déjerine-Roussy syndrome” — affects 2–8% of all stroke survivors and up to 25% of those with thalamic lesions. It results from damage to the spinothalamic pathway at any level (thalamus, brainstem, or somatosensory cortex), causing deafferentation and central sensitization. The condition is frequently misdiagnosed as musculoskeletal pain, radiculopathy, or psychosomatic complaints.

Clinical Features

• Character: Constant or intermittent burning, stinging, aching, squeezing, or lancinating pain — described by patients as “unlike anything I’ve experienced before.” Often difficult to articulate.
• Distribution: Corresponds to the stroke-affected body territory — not a dermatomal or peripheral nerve distribution. May affect an entire hemibody or a more limited region.
• Allodynia: Pain from normally non-painful stimuli (light touch, clothing on skin, breeze, temperature changes) is pathognomonic. Patients may avoid wearing sleeves on the affected arm or tolerate only loose clothing.
• Dysesthesia: Unpleasant abnormal sensations — tingling, pins and needles, electric-like — that occur spontaneously or are evoked by stimuli.
• Onset: Typically weeks to months after stroke (not immediate). Rarely can present acutely. Median onset ~3–6 months, though delayed onset >1 year is reported.
• Examination: Altered sensory examination in the affected area — particularly impaired temperature and pinprick sensation (spinothalamic modalities), often with preserved light touch and proprioception (dorsal column modalities). This dissociation is a useful clinical sign.

Treatment Algorithm

Important: Opioids are generally ineffective for CPSP and are not recommended. The central sensitization mechanism differs fundamentally from nociceptive pain, and opioids carry additional risks of sedation, falls, cognitive impairment, and dependence in stroke patients. Combination therapy (e.g., amitriptyline + lamotrigine, or pregabalin + duloxetine) is often needed when single agents provide incomplete relief.

8. Hemiplegic Shoulder Pain

Hemiplegic shoulder pain (HSP) affects 20–70% of stroke patients with upper limb weakness, making it the most common pain syndrome after stroke. It impairs rehabilitation participation, limits functional recovery, disrupts sleep, and contributes to depression. The etiology is almost always multifactorial — multiple pathological processes coexist in the same shoulder, requiring systematic evaluation.

Causes and Mechanisms

Prevention

Prevention is far more effective than treatment for hemiplegic shoulder pain. The following practices should begin on day 1 of admission:

• Proper positioning: Support the affected arm on a pillow or armrest at all times — in bed (arm on pillow, shoulder protracted, slight abduction), in wheelchair (arm on lap tray or armrest), in standing (arm in sling if flaccid and weight-bearing). Avoid letting the arm hang dependently.
• Handling precautions — the cardinal rule: NEVER pull the affected arm. When assisting with transfers, support from the trunk and unaffected side. Avoid overhead pulleys (excessive abduction with weak rotator cuff causes impingement). Nurses, therapists, and family must all be educated.
• Early gentle ROM: Begin passive range of motion within pain-free limits within 24–48 hours. Avoid forcing abduction beyond 90° or external rotation beyond comfortable range in a flaccid arm.
• Shoulder support: Slings are controversial — they prevent subluxation but may promote flexion synergy patterns and reduce arm use. Use judiciously: during ambulation/transfers when the arm is unsupported, remove during seated activities and therapy. Lap trays in wheelchair provide continuous support without the disadvantages of slings.

Treatment by Etiology

9. Spasticity-Pain Overlap

Spasticity and pain are intimately connected in stroke patients, and treating one often improves the other. This section serves as a bridge to the standalone spasticity management article.

Spasticity-related pain is nociceptive — it arises from sustained muscle contraction, joint stress, and secondary musculoskeletal changes (contractures, tendon shortening, joint subluxation). It is typically described as aching, cramping, or tightness, worsened by movement or position changes, and localized to spastic muscle groups. It improves with botulinum toxin injection, stretching, and antispastic medications.

Central post-stroke pain is neuropathic — it arises from damage to central somatosensory pathways and presents as burning, stinging, or allodynia. It responds to TCAs, anticonvulsants, and neuromodulation, NOT to stretching or botulinum toxin.

In many patients, both types coexist. A patient with hemiplegic shoulder pain may have spasticity-mediated impingement (treat with botulinum toxin to internal rotators) AND central post-stroke pain in the same arm (treat with amitriptyline). Systematic evaluation that distinguishes nociceptive from neuropathic components enables targeted, effective treatment rather than the frustrating trial-and-error that occurs when pain is treated as a single entity.

10. Trial Comparison Table